NCT05363839

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

A Phase 1, Single-center, Placebo-controlled, Double-blind, Randomized Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of ACH-000029 in Healthy Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Syneos Health · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Randomized single ascending dose placebo controlled treatment of ACH-000029 administered orally via capsule in healthy volunteers.

Detailed description

This study will be conducted in up to 3 dosing groups of 8 total subjects each. The purpose of this trial is to determine the safety and tolerability of a single dose of ACH-000029 or placebo.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ACH-000029	ACH-000029 will be administered orally via a capsule.
DRUG	Placebo	Placebo will be administered orally via a capsule.

Timeline

• Start date: 2022-05-06
• Primary completion: 2022-11-02
• Completion: 2022-11-02
• First posted: 2022-05-06
• Last updated: 2023-04-27

Locations

1 site across 1 country: Australia